Company intelligence / Profile preview
Ampersand Biomedicines
Boston, Massachusetts, USAampersand.bio ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead candidate AMP-410 showed strong efficacy in preclinical models of hard-to-treat cancers compared to four other clinical-stage immunotherapies. AMP-410 monotherapy achieved 90% tumor-free survival in colorectal cancer and extended survival in melanoma models; when combined with anti-PD-1, it drove 100% tumor-free survival in colorectal cancer.[6]
- Therapeutic areas
- OncologyImmunologyEndocrinology
- Modalities
- BiologicsAND-Body™ Therapeutics (programmable biologic medicines)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Eli Lilly & CompanyPfizerPioneering Medicines (Flagship's in-house drug discovery and development unit)
Beyond the preview
Go deeper on Ampersand Biomedicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ampersand Biomedicines.